Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FGF12 antisense RNA 2 (non-protein coding) (FGF12-AS2)
- Target
- FGF12-AS2
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
FGF12 antisense RNA 2 (FGF12-AS2) is a long non-coding RNA (lncRNA), meaning it does not encode a protein. FGF12-AS2 acts at the RNA level to regulate gene expression and cellular processes. It is reported to promote proliferation, migration, invasion, and epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC), while its silencing inhibits NSCLC cell growth and induces apoptosis. High expression of FGF12-AS2 has been identified as part of prognostic risk models in glioblastoma (GBM) and may serve as a prognostic biomarker for GBM as well as other cancers[6][2]. There are currently no known direct drugs or therapeutic interventions targeting FGF12-AS2, and it is not recognized as a classical therapeutic target (such as a receptor, enzyme, or transporter) but may be relevant as a biomarker or as a future candidate for RNA-based therapies.
- Other names
- FGF12-AS2FGF12 antisense RNA 2FGF12 antisense RNA 2 (non-protein coding)
02
Biological functions
Regulation of gene expressionPromotion of cell proliferationInhibition of apoptosisEnhancement of cell migration and invasionRegulation of epithelial-mesenchymal transition (EMT)
03
Disease associations
CancerSpecifically, non-small cell lung cancer (NSCLC)Possibly glioblastoma (GBM)
04
Biomarkers
Prognostic biomarker in glioblastoma (GBM) and potentially other cancersBiomarker for NSCLC progression
Beyond the preview
Go deeper on FGF12 antisense RNA 2 (non-protein coding) (FGF12-AS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FGF12 antisense RNA 2 (non-protein coding) (FGF12-AS2).